Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Handling worker and third-party exposures to nanotherapeutics during clinical trials.

Ramachandran G, Howard J, Maynard A, Philbert M.

J Law Med Ethics. 2012 Winter;40(4):856-64. doi: 10.1111/j.1748-720X.2012.00714.x.

PMID:
23289688
2.

Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field.

Fatehi L, Wolf SM, McCullough J, Hall R, Lawrenz F, Kahn JP, Jones C, Campbell SA, Dresser RS, Erdman AG, Haynes CL, Hoerr RA, Hogle LF, Keane MA, Khushf G, King NM, Kokkoli E, Marchant G, Maynard AD, Philbert M, Ramachandran G, Siegel RA, Wickline S.

J Law Med Ethics. 2012 Winter;40(4):716-50. doi: 10.1111/j.1748-720X.2012.00703.x.

3.

Bloodborne pathogens. What you need to know--Part I.

Twitchell KT.

AAOHN J. 2003 Jan;51(1):38-45; quiz 46-7. Review.

PMID:
12596344
4.
5.

Employee health surveillance in the health care industry.

Hood J, LarraƱaga M.

AAOHN J. 2007 Oct;55(10):423-31. Review.

PMID:
17969540
6.

Risk assessment and risk management of nanomaterials in the workplace: translating research to practice.

Kuempel ED, Geraci CL, Schulte PA.

Ann Occup Hyg. 2012 Jul;56(5):491-505. doi: 10.1093/annhyg/mes040. Review.

PMID:
22752094
7.

Preventing occupational exposures to antineoplastic drugs in health care settings.

Connor TH, McDiarmid MA.

CA Cancer J Clin. 2006 Nov-Dec;56(6):354-65. Review.

8.

Assessing workplace compliance with handling of antineoplastic agents.

Gambrell J, Moore S.

Clin J Oncol Nurs. 2006 Aug;10(4):473-7. Review.

PMID:
16927900
9.

The impact of U.S. policies to protect healthcare workers from bloodborne pathogens: the critical role of safety-engineered devices.

Jagger J, Perry J, Gomaa A, Phillips EK.

J Infect Public Health. 2008;1(2):62-71. doi: 10.1016/j.jiph.2008.10.002. Epub 2008 Nov 26. Review.

10.

Ethics in nanomedicine.

Resnik DB, Tinkle SS.

Nanomedicine (Lond). 2007 Jun;2(3):345-50. Review.

11.

Risks to health care workers from nano-enabled medical products.

Murashov V, Howard J.

J Occup Environ Hyg. 2015;12(6):D75-85. doi: 10.1080/15459624.2015.1006641. Review.

PMID:
25950806
12.

Latex allergy in health care workers. What are the risks?

Karvonen CA.

AAOHN J. 1999 Nov;47(11):519-25. Review.

PMID:
10865539
13.

Management of nanomaterials safety in research environment.

Groso A, Petri-Fink A, Magrez A, Riediker M, Meyer T.

Part Fibre Toxicol. 2010 Dec 10;7:40. doi: 10.1186/1743-8977-7-40. Review.

14.

Risk management frameworks for human health and environmental risks.

Jardine C, Hrudey S, Shortreed J, Craig L, Krewski D, Furgal C, McColl S.

J Toxicol Environ Health B Crit Rev. 2003 Nov-Dec;6(6):569-720. Review.

PMID:
14698953
15.

Tuberculosis in the workplace: a labor perspective.

Cohen J, Kenny L.

Occup Med. 1994 Oct-Dec;9(4):659-70. Review.

PMID:
7878493
16.

Surgical smoke--is there a fire?

Andersen E.

AAOHN J. 2005 Mar;53(3):103-4. Review. No abstract available.

PMID:
15789964
17.

Workplace practices for engineered nanomaterial manufacturers.

Woskie S.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010 Nov-Dec;2(6):685-92. doi: 10.1002/wnan.101. Review.

PMID:
20593453
18.

Universal precautions: an update.

Gershon RR, Karkashian C, Felknor S.

Heart Lung. 1994 Jul-Aug;23(4):352-8. Review.

PMID:
7960863
19.

Health effects of anesthetic gases.

Suruda A.

Occup Med. 1997 Oct-Dec;12(4):627-34. Review.

PMID:
9353812
20.

General principles of medical surveillance: implications for workers potentially exposed to nanomaterials.

Trout DB.

J Occup Environ Med. 2011 Jun;53(6 Suppl):S22-4. doi: 10.1097/JOM.0b013e31821b1e45. Review.

Supplemental Content

Support Center